Ligand News and Research

RSS

A faster, cheaper method to detect immune autoantibodies in whole blood

Researchers developed a quick and affordable whole-blood assay to detect autoantibodies against type I IFNs, enabling rapid diagnostics for immune disorders. This new method has potential clinical impact by addressing key limitations of current tests.

25 Sep 2024

Liraglutide activates key brain circuits to trigger weight loss in obesity

Researchers uncover how liraglutide targets specific brain regions to suppress appetite and promote significant weight loss through GLP-1 receptor activation.

23 Sep 2024

FORT-2 trial shows promising results for bladder cancer immunotherapy combination

Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and tolerable in patients with locally advanced or metastatic bladder cancer.

19 Sep 2024

Novel delivery platform enhances effectiveness of cancer immunotherapy and reduces side effects

Immunotherapy is a type of cancer treatment that uses the body's own immune system to help fight cancer. This is by stimulating the immune response to recognize and attack cancer cells more effectively.

16 Sep 2024

ISM2196: A promising AI-developed WRN inhibitor for advanced metastatic cancers

Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the nomination of ISM2196, an AI-driven, potential best-in-class small molecule WRN inhibitor targeting advanced metastatic microsatellite instability (MSI) cancers guided by synthetic lethality strategy.

13 Sep 2024

Study reveals how sex hormones regulate immune system functions

Findings indicate that testosterone therapy in trans men alters immune system responses, suggesting implications for disease susceptibility and treatment.

6 Sep 2024

Review explores WNT5B and WNT10B roles in osteosarcoma

A new review was published in Oncotarget's Volume 15 on August 2, 2024, entitled, "Targeting WNT5B and WNT10B in osteosarcoma."

4 Sep 2024

Scientists discover key to activating natural killer cells against cancer

Scientists are on the verge of a cancer breakthrough after working out how the body's immune system targets cells devastated by the disease.

28 Aug 2024

Maternal gut bacteria linked to changes in fetal brain metabolism

The impact of Bifidobacterium breve's presence in the maternal gut during pregnancy on fetal brain metabolism.

23 Aug 2024

How persistent organic pollutants affect gut health: findings on metabolic disruptions and microbiota changes

Early life exposure to potent AHR agonists on gut microbiota and its potential effects on metabolic health later in life.

20 Aug 2024

New targets for improved cancer immunotherapy

In the past two decades, immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, showing promising results against various solid tumors. This study reviews recent developments in ICIs, focusing on new targets like T cell immunoreceptors with Ig and ITIM domains (TIGIT), T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), and lymphocyte activation gene-3 (LAG-3). These targets aim to overcome resistance mechanisms limiting the effectiveness of current therapies, such as anti-PD-1 and anti-CTLA-4. By identifying and developing these new ICIs, researchers hope to improve treatment outcomes and provide new therapeutic options for cancer patients.

14 Aug 2024

AlphaFold accelerates discovery of potential antipsychotic drugs by outperforming traditional methods

Researchers used AlphaFold and homology modeling to identify potent TAAR1 agonists, showing AlphaFold's superior performance in drug discovery for neuropsychiatric conditions.

13 Aug 2024

Review of fasting-mimicking diets in cancer treatment

Researchers present the role of cyclic fasting and fasting-mimicking diets (FMD) in cancer therapy.

8 Aug 2024

FDA accepted PD-L1 inhibitor durvalumab for the treatment of endometrial cancer

On June 14, 2024, the U.S. FDA approved AstraZeneca's Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch repair deficiency. Endometrial cancer is the most prevalent gynecologic cancer, with an estimated 66,200 new U.S. cases in 2023.

From Sino Biological Inc. 5 Aug 2024

Study elucidates mechanisms behind G protein selectivity and efficacy in adenosine A2A receptor

In a groundbreaking study, a multinational research team led by Dr. Adnan Sljoka (RIKEN) and Prof. Akio Kitao (Tokyo Tech), in collaboration with Prof. Scott Prosser (University of Toronto), has carried out experimental and computational studies to elucidate the mechanisms behind G protein selectivity and efficacy in the human adenosine A2A receptor (A2AR).

1 Aug 2024

Study unveils dual roles of TNF-α receptors in tissue regeneration and cell death

A study published in The EMBO Journal opens new perspectives to better understand how the molecular mechanisms involved in regenerative medicine work.

29 Jul 2024

Study finds genetic factors key to post-stroke cardiovascular risks

Research identifies genetic and molecular risk factors for cardiovascular outcomes after an initial stroke, uncovering potential therapeutic targets to improve patient prognoses.

28 Jul 2024

Proteomic signatures enhance risk prediction for both common and rare diseases

Researchers have developed sparse prediction models combining plasma proteins and clinical data to predict the 10-year risk of 218 diseases. The study, involving over 41,000 participants, highlights the enhanced predictive power of proteomic signatures.

24 Jul 2024

Concussions in retired rugby players linked to higher neurodegenerative disease biomarkers

A study in the International Journal of Molecular Sciences reveals that retired rugby players with a history of concussions exhibit significant differences in biomarkers associated with neurodegenerative diseases compared to non-contact sports participants.

21 Jul 2024

Leveraging antibodies as a drug delivery mechanism may prove useful in the treatment of cancers

The primary goal in cancer drug research is not merely to discover compounds that can destroy cancer cells, but to develop methods that specifically target and deliver these agents to cancer cells, sparing healthy ones.

11 Jul 2024